These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 22723116)

  • 61. [Cilostazol is effective and safe option for the treatment of intermittent claudication. Results of the NOCLAUD study].
    Farkas K; Járai Z; Kolossváry E
    Orv Hetil; 2017 Jan; 158(4):123-128. PubMed ID: 28116935
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The role of cilostazol in the treatment of intermittent claudication.
    Barnett AH; Bradbury AW; Brittenden J; Crichton B; Donnelly R; Homer-Vanniasinkam S; Mikhailidis DP; Stansby G
    Curr Med Res Opin; 2004 Oct; 20(10):1661-70. PubMed ID: 15462700
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Exercise and peripheral arterial disease.
    Kim DH
    Ann Intern Med; 2006 May; 144(9):699; author reply 699-700. PubMed ID: 16670144
    [No Abstract]   [Full Text] [Related]  

  • 64. [Cilostazol improves the quality of life and lower-limb functional capacity also in diabetic patients].
    Farkas K; Kolossváry E; Járai Z
    Orv Hetil; 2020 Sep; 161(38):1637-1645. PubMed ID: 32924968
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of cilostazol prescribed in a pragmatic treatment program for intermittent claudication.
    Lee C; Nelson PR
    Vasc Endovascular Surg; 2014 Apr; 48(3):224-9. PubMed ID: 24399131
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Studies on the effectiveness and safety of cilostazol, beraprost sodium, prostaglandin E1 for the treatment of intermittent claudication.
    Hashiguchi M; Ohno K; Saito R
    Yakugaku Zasshi; 2004 Jun; 124(6):321-32. PubMed ID: 15170067
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
    Hiatt WR; Money SR; Brass EP
    J Vasc Surg; 2008 Feb; 47(2):330-336. PubMed ID: 18155871
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Three-curve rocker-soled shoes and gait adaptations to intermittent claudication pain: A randomised crossover trial.
    Jordan AR; Tew GA; Hutchins SW; Shalan A; Cook L; Thompson A
    Gait Posture; 2019 Jan; 67():31-36. PubMed ID: 30265963
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Systematic review the efficacy and safety of cilostazol, pentoxifylline, beraprost in the treatment of intermittent claudication: A network meta-analysis.
    Liang X; Wang Y; Zhao C; Cao Y
    PLoS One; 2022; 17(11):e0275392. PubMed ID: 36318524
    [TBL] [Abstract][Full Text] [Related]  

  • 70. L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial.
    Goldenberg NA; Krantz MJ; Hiatt WR
    Vasc Med; 2012 Jun; 17(3):145-54. PubMed ID: 22615190
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Relationship between temporal-spatial gait parameters, gait kinematics, walking performance, exercise capacity, and physical activity level in peripheral arterial disease.
    Crowther RG; Spinks WL; Leicht AS; Quigley F; Golledge J
    J Vasc Surg; 2007 Jun; 45(6):1172-8. PubMed ID: 17543681
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A randomized trial of iloprost in patients with intermittent claudication.
    Creager MA; Pande RL; Hiatt WR
    Vasc Med; 2008 Feb; 13(1):5-13. PubMed ID: 18372433
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Supervised walking exercise therapy improves gait biomechanics in patients with peripheral artery disease.
    Schieber MN; Pipinos II; Johanning JM; Casale GP; Williams MA; DeSpiegelaere HK; Senderling B; Myers SA
    J Vasc Surg; 2020 Feb; 71(2):575-583. PubMed ID: 31443974
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of cilostazol on lipid and fatty acid metabolism.
    Nakamura N; Osawa H; Yamabe H; Okumura K; Hamazaki T
    Clin Exp Med; 2005 Mar; 4(4):170-3. PubMed ID: 15750763
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication.
    Brass EP; Cooper LT; Morgan RE; Hiatt WR
    J Vasc Surg; 2012 Feb; 55(2):381-389.e1. PubMed ID: 22119244
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Prospects of clinical application of cilostazol for peripheral artery disease].
    Burleva EP; Korelin SV
    Angiol Sosud Khir; 2020; 26(3):28-36. PubMed ID: 33063749
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacotherapy for peripheral arterial disease: emerging therapeutic options.
    Jaff MR
    Angiology; 2002; 53(6):627-33. PubMed ID: 12463615
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Peripheral arterial disease affects kinematics during walking.
    Celis R; Pipinos II; Scott-Pandorf MM; Myers SA; Stergiou N; Johanning JM
    J Vasc Surg; 2009 Jan; 49(1):127-32. PubMed ID: 19028062
    [TBL] [Abstract][Full Text] [Related]  

  • 79. NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model.
    Ishiwata N; Noguchi K; Kawanishi M; Asakura Y; Hori M; Mitani A; Ito Y; Takahashi K; Nishiyama H; Shudo N; Takahashi S; Takahashi K; Tsuruzoe N; Nakaike S
    Life Sci; 2007 Sep; 81(12):970-8. PubMed ID: 17850826
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Makar RR; McEneny J; Young IS; Lee B; Soong CV
    Eur J Vasc Endovasc Surg; 2009 Mar; 37(3):326-35. PubMed ID: 19112032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.